此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation (ABRAXAS)

2026年9月3日 更新者:Mehdi Hamadani、Medical College of Wisconsin

Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.

研究概览

详细说明

This study will determine if axatilimab in combination with standard of care posttransplant cyclophosphamide + tacrolimus/mycophenolate mofetil is safe, tolerable, and efficacious as GVHD prophylaxis in a population of adult patients with hematologic malignancies receiving a first HLA-matched related or unrelated donor myeloablative allogeneic HCT.

研究类型

介入性

注册 (估计的)

72

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Medical College of Wisconsin Cancer Center Clinical Trials Office
  • 电话号码:8900 866-680-0505
  • 邮箱:cccto@mcw.edu

学习地点

    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • Froedtert & the Medical College of Wisconsin
        • 接触:
        • 首席研究员:
          • Sameem Abedin, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥18 years.
  • Patients with a history of a hematologic malignancy with a planned myeloablative conditioning (MAC) peripheral blood allogeneic HCT.

    a. Note: Patients with acute leukemia must be in morphologic complete remission with or without hematologic recovery with ≤5% blasts in the bone marrow. Patients with Chronic Myelomonocytic Leukemia (CMML) must have a white blood cell (WBC) count ≤10,000 cells/µL and ≤5% blasts in the marrow. Patients with ≥5% blasts due to a regenerating marrow must contact the protocol chairs for review. Patients with a diagnosis of myelofibrosis require sponsor approval before enrolling.

  • Patients must be receiving an allograft from a suitable HLA-matched sibling or (7/8 or 8/8) unrelated donor according to transplant center's guidelines (for selection of appropriate donor).
  • The following laboratory values obtained ≤14 days prior to registration/randomization:

    1. Total bilirubin ≤1.5 x ULN or total bilirubin ≤3.0 x the Upper Limit of Normal (ULN) in the presence of Gilbert's syndrome. If total bilirubin is abnormal (≥1.5 x ULN), assess direct bilirubin. NOTE: Patients with Gilbert Syndrome and elevated baseline unconjugated (indirect) bilirubin up to 3.0 mg/dL are eligible. Gilbert syndrome should be confirmed by the presence of UGT1A1*28 variant.
    2. Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 x ULN).
    3. Calculated creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula below:

Creatinine clearance for males = (140 - age)(weight in kg) /(72)(serum creatinine in mg⁄dL) Creatinine clearance for females = (140 - age)(weight in kg) (0.85) /(72)(serum creatinine in mg⁄dL)

  • Negative serum pregnancy test done ≤7 days prior to registration/randomization, for persons of childbearing potential only.
  • Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 3 months after the last dose of study drug.

    a. Note: The following are considered effective contraceptives: oral contraceptive pill; condom plus spermicide; diaphragm plus spermicide; patient or partner surgically sterile; patient or partner more than 12 months postmenopausal; or injectable or implantable agent/device. Male patients should refrain from sperm donation and female patients should refrain from breastfeeding throughout this period.

  • Ability to understand and provide written informed consent at the time of initial study enrollment. Participants who later lose decisional capacity may remain on study with consent from a legally authorized representative (LAR), as applicable.
  • Willingness to provide mandatory blood and bone marrow aspirate specimens for correlative research.
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion Criteria:

  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effect on the developing fetus and newborn are unknown:

    1. Pregnant persons.
    2. Nursing persons.
    3. Persons of childbearing potential, and persons able to father a child, who are unwilling to employ adequate contraception.
  • Any of the following current or prior therapies:

    1. Patients receiving a cord blood transplant.
    2. Patients undergoing a T-cell depleted allogeneic transplantation (using ex vivo CD34 selection, or with serotherapy [antithymocyte globulin or alemtuzumab]).
    3. Patients undergoing a second allogeneic transplant (after a previous allogeneic transplant).
    4. Pre-planned treatment with JAK1/JAK2 inhibitor after transplant.
    5. Previous exposure to axatilimab.
    6. Receiving an investigational treatment ≤28 days prior to registration/randomization.
    7. Major surgery ≤3 weeks prior to registration/randomization.
    8. Chemotherapy ≤2 weeks prior to registration/randomization unless chemotherapy is part of the pre-transplant conditioning.
    9. Radiation therapy ≤2 weeks prior to registration/randomization unless radiation is part of the pre-transplant conditioning.
    10. Planned use of Donor Lymphocyte Infusion (DLI) therapy.
    11. Exception: Use of maintenance regimens as routine clinical care will be permitted but must be declared prior to registration/randomization. The trial does not restrict subsequent treatment after meeting the GFS endpoint.
  • Active central nervous system (CNS) involvement by malignant cells.
  • Leukemia involvement in the CNS ≤4 weeks of registration for patients with a history of prior CNS leukemia involvement (i.e., leukemic blasts previously detected in the cerebral spinal fluid).
  • History of acute or chronic pancreatitis.
  • History of myositis.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Patients with active hepatitis B or C.

    a. Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable.

  • Any known infection with human immunodeficiency virus (HIV), HTLV-1.
  • Uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at the time of registration/randomization.
  • Psychiatric illness/social situations that would limit compliance with study requirements.
  • Diagnosed with another malignancy (other than malignancy for which transplant was performed) ≤ 3 years of registration/randomization, unless previously treated with curative intent and approved by PI (e.g., but not limited to completely resected basal cell, squamous cell, or ductal carcinoma in situ, or low-risk prostate cancer after curative resection or on watchful waiting). In patients with transformed disease (e.g. aggressive lymphoma evolving from CLL, or acute leukemia from MDS), the original hematological disorder is not considered an exclusion. Cancer treated with curative intent <3 years previously will not be allowed unless approved by any of the Study Chairs.
  • History of myocardial infarction ≤6 months, or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Safety Run-in
An early safety analysis will be performed after the first 6 evaluable patients have been accrued to Dose Level 1 of the study and observed for four cycles of axatilimab (Cycles 1-4). Accrual will be temporarily halted while these patients are evaluated. If 2 or more of the first 6 patients experience a significant toxicity, then the protocol may be amended and the dose of axatilimab may be de-escalated to Dose Level -1.
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
其他名称:
  • 胞毒素
  • 新星
  • 胞磷烷
Tacrolimus will be given per institutional practices, starting on Day +5. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).
The dose is dependent on the results of the safety run-in. The starting dose of the safety run-in is 0.3 mg/kg (maximum of 35 mg). If Dose Level 1 has an unacceptable level of toxicity (≥2 patients having significant toxicity), then axatilimab may be de-escalated to 0.2 mg/kg (maximum of 23 mg).
其他名称:
  • 尼克季姆沃
  • axatilimab-csfr
实验性的:Axatilimab Treatment
Starts 35 (±5) days from stem cell transplant; Dosing will occur every 14 days for a maximum of 12 cycles.
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
其他名称:
  • 胞毒素
  • 新星
  • 胞磷烷
Tacrolimus will be given per institutional practices, starting on Day +5. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).
The dose is dependent on the results of the safety run-in. The starting dose of the safety run-in is 0.3 mg/kg (maximum of 35 mg). If Dose Level 1 has an unacceptable level of toxicity (≥2 patients having significant toxicity), then axatilimab may be de-escalated to 0.2 mg/kg (maximum of 23 mg).
其他名称:
  • 尼克季姆沃
  • axatilimab-csfr
实验性的:No Axatilimab Treatment
Starts 35 (±5) days from stem cell transplant.
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
其他名称:
  • 胞毒素
  • 新星
  • 胞磷烷
Tacrolimus will be given per institutional practices, starting on Day +5. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
GVHD-free survival
大体时间:1 Year Post HCT
A patient will be considered a success for 1-year GVHD-free survival if they are alive without Grade 3 or 4 acute GVHD or systemic immunosuppression requiring chronic GVHD at one year post transplant. Death, Grade 3 or 4 acute GVHD, and immunosuppression-requiring chronic GVHD (of any severity) prior to 1 year will be considered as events.
1 Year Post HCT

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sameem Abedin, MD、Medical College of Wisconsin
  • 学习椅:Mehdi Hamadani, MD、Medical College of Wisconsin

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2031年11月1日

研究完成 (估计的)

2031年11月1日

研究注册日期

首次提交

2026年9月3日

首先提交符合 QC 标准的

2026年9月3日

首次发布 (实际的)

2026年9月8日

研究记录更新

最后更新发布 (实际的)

2026年9月8日

上次提交的符合 QC 标准的更新

2026年9月3日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅